Entos collects $53M to bring quantum tech to AI drug design

On July 14th, 2021, Fierce Biotech reported: The advent of artificial intelligence and machine learning already promises to shave months to years off of the typical drug discovery timeline—but why stop there? Entos believes it can make the process even faster while using fewer data resources, and it’s raised $53 million to help catapult its efforts.

The California-based startup’s series A round was co-led by the tech investment firms Coatue and Catalio Capital Management, with additional investments from OrbiMed, Sequoia Capital, Nexus Ventures and Freeflow.

They’re backing Entos’ OrbNet platform, which incorporates features of quantum mechanics into its drug-designing algorithms. The company aims to leap-frog the traditional trade-offs seen between accuracy and computational requirements, by predicting the molecular energies at play within a compound’s nuclear structure.

Read full article here